UNSPSC 51111859: Mecasermin

This classification denotes a therapeutic insulin-like growth factor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7GR9I2683O. European Medicines Agency schedules Mecasermin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08672MIG. Mecasermin generally arises in the molecular formula C331H512N94O101S7.

The term MECASERMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, no, 3 1992, list 32.) MECASERMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Mecasermin under HS 29371900 and SITC 54154. SMILES:. As of Q4 2014, MECASERMIN remains the US FDA Preferred Term for this commodity.. Mecasermin bears US NLM identifiers UMLS ID C0904505 and NCI Concept Code C2262.

UNSPSC 51111859 Mecasermin is a Commodity code covering a recombinant insulin-like growth factor (IGF-1) medication used to treat growth disorders in pediatric patients with severe primary insulin-like growth factor deficiency. State and local governments procure mecasermin primarily through Medicaid programs, state health departments, and institutional healthcare systems serving eligible beneficiaries. The product is administered by injection and requires ongoing clinical monitoring; procurement typically follows pharmaceutical contracting frameworks that include volume forecasting, manufacturer rebate agreements, and formulary management protocols standard to state Medicaid drug programs.

The source material provides no recent state and local contract opportunities tagged to this Commodity code. The absence of posted RFP, RFQ, IFB, or ITB notices under this code reflects the nature of pharmaceutical procurement at the state and local level — mecasermin contracting occurs through standing Medicaid rebate agreements, state pharmaceutical benefit manager contracts, and institutional formulary adoption processes rather than through discrete competitive solicitations. Pursuit of this code requires engagement with state Medicaid agencies' drug program offices, institutional pharmacy directors at large health systems, and participation in state and regional group purchasing networks, but prospecting should focus on direct relationship-building with these entities rather than on monitoring this code's procurement-notice channels.